Evidence map›Paper›PMID 32690600›Full record

Observational studyGut2021

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19.

Tao Zuo, Qin Liu, Fen Zhang, Grace Chung-Yan Lui, Eugene Yk Tso, Yun Kit Yeoh, Zigui Chen, Siaw Shi Boon, Francis Kl Chan, Paul Ks Chan and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 313 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
313citing papers in PubMed, 7 pooled it
33.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04517422 nacompletednot on this map

Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial

TypeinterventionalSponsorAB Biotics, SARan2020 to 2021Enrolled300ConditionsSARS-CoV InfectionArmsProbiotics, Placebo
NCT04884776 naunknown statusnot on this map

Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic

TypeinterventionalSponsorChinese University of Hong KongRan2021 to 2024Enrolled453ConditionsGut Microbiota, COVID-19 VaccineArmsMicrobiome immunity formula, Active placebo
3 · Its place in the literature

Who cites it

313 citing papers in PubMed, 7 syntheses or guidelines pooled it, 470 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Gut distress and interventionFrontiers in public health · 2023
    Pooled it
  5. COVID-19 alters human microbiomes: a meta-analysis.Frontiers in cellular and infection microbiology · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. VSL#3British journal of biomedical science · 2026
    Trial
  9. Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

253 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Tao Zuo *Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.ORCID 0000-0001-8450-5281
Qin Liu *Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Fen Zhang *Center for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Grace Chung-Yan LuiDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Eugene Yk TsoDepartment of Medicine and Geriatrics, United Christian Hospital, Hong Kong, Hong Kong.
Yun Kit YeohCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.ORCID 0000-0003-0241-6117
Zigui ChenCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.ORCID 0000-0002-8577-1298
Siaw Shi BoonDepartment of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Francis Kl ChanCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.ORCID 0000-0001-7388-2436
Paul Ks ChanCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Siew C NgCenter for Gut Microbiota Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, China siewchienng@cuhk.edu.hk.ORCID 0000-0002-6850-4454
Chinese University of Hong Kong · HKUnited Christian Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAlthough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected in faeces of patients with COVID-19, the activity and infectivity of the virus in the GI tract during disease course is largely unknown. We investigated temporal transcriptional activity of SARS-CoV-2 and its association with longitudinal faecal microbiome alterations in patients with COVID-19.

designWe performed RNA shotgun metagenomics sequencing on serial faecal viral extractions from 15 hospitalised patients with COVID-19. Sequencing coverage of the SARS-CoV-2 genome was quantified. We assessed faecal microbiome composition and microbiome functionality in association with signatures of faecal SARS-CoV-2 infectivity.

resultsSeven (46.7%) of 15 patients with COVID-19 had stool positivity for SARS-CoV-2 by viral RNA metagenomic sequencing. Even in the absence of GI manifestations, all seven patients showed strikingly higher coverage (p=0.0261) and density (p=0.0094) of the 3' vs 5' end of SARS-CoV-2 genome in their faecal viral metagenome profile. Faecal viral metagenome of three patients continued to display active viral infection signature (higher 3' vs 5' end coverage) up to 6 days after clearance of SARS-CoV-2 from respiratory samples. Faecal samples with signature of high SARS-CoV-2 infectivity had higher abundances of bacterial species

conclusionThis pilot study provides evidence for active and prolonged 'quiescent' GI infection even in the absence of GI manifestations and after recovery from respiratory infection of SARS-CoV-2. Gut microbiota of patients with active SARS-CoV-2 GI infection was characterised by enrichment of opportunistic pathogens, loss of salutary bacteria and increased functional capacity for nucleotide and amino acid biosynthesis and carbohydrate metabolism.

Indexed as

AdultAgedCOVID-19FecesFemaleGastrointestinal MicrobiomeHospitalizationHumansLongitudinal StudiesMaleMiddle AgedPilot ProjectsProspective StudiesSARS-CoV-2Young Adultdiagnostic virologygut inflammationinfectious disease

Identifiers

PMID32690600
PMCPMC7385744
OpenAlexW3042232275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.